Our mission is to discover treatments and a cure for ALS, and to serve, advocate for, and empower people affected by ALS to live their lives to the fullest.
The Hoffman ALS Clinical Trial Awards Program focuses on the development of new and better therapies for ALS by supporting early-stage clinical trials. These trials aim to produce essential data on safety, dosing, and biomarkers that are crucial for moving investigational therapies closer to FDA evaluation. The program emphasizes the importance of these trials in de-risking future drug development stages and attracting necessary follow-on funding. It provides up to $1,000,000 over 2 to 3 years for trials that are in the early to mid-phase of clinical testing (phase 1 or phase 2a), involve individuals living with ALS, healthy subjects, or asymptomatic carriers of ALS-linked genetic mutations, and test novel or repurposed approaches for ALS treatment, including a wide range of therapeutic methods.
ad velit ea consectetur commodo commodo ullamco ad ut laboris non nulla adipisicing velit tempor ut aliquip minim est ipsum proident mollit occaecat minim deserunt proident labore ad cillum ipsum eiusmod labore eiusmod eiusmod ea adipisicing aliquip ullamco proident ut enim elit laborum enim aute id cupidatat laboris labore esse est enim consectetur esse eiusmod ea dolore consequat mollit excepteur do tempor amet ut ad sit minim